- Survival Outcomes of Concurrent Treatment with Docetaxel and Androgen Deprivation Therapy in Metastatic Castration-Resistant Prostate Cancer
-
Jang HS, Koo KC, Cho KS, Chung BH
- KMID: 2374150
- Yonsei Med J.
- 2016 Sep;57(5):1070-1078.
- doi: 10.3349/ymj.2016.57.5.1070
PURPOSE: Docetaxel-based chemotherapy (DTX) improves overall survival (OS) of men with metastatic castration-resistant prostate cancer (mCRPC). Considering the potential existence of androgen receptors that remain active at this stage, we... -
- CITED
-
- Close
- SHARE
-
- Close
